Core Insights - Becton, Dickinson and Co. (BDX) is a multinational medical technology company focused on manufacturing and selling medical devices, instruments, and reagents globally [1] Financial Performance - The company is set to report its Q4 2025 earnings on November 6, with analysts expecting an EPS of $3.92, an increase from $3.81 in the prior year [2] - Quarterly revenue is anticipated to reach $5.92 billion, up from $5.44 billion a year earlier [2] - In Q3 2025, Becton Dickinson reported an adjusted EPS of $3.68, exceeding the consensus estimate of $3.41, and revenues of $5.51 billion, slightly above the consensus of $5.49 billion [3] Growth and Strategic Initiatives - The CEO highlighted an increase in organic growth trajectory in Q3, along with strong margin and EPS growth, which led to a raised EPS guidance for the full year [4] - The full-year 2025 adjusted EPS guidance has been raised to a range of $14.30 to $14.45, reflecting a $0.18 increase and a 9.4% growth at the midpoint [4] - An agreement was announced to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, aimed at creating a leader in life sciences and diagnostics focused on high-volume testing [4]